The Ninth British Medical Research Council Trial for the Treatment of Acute Myeloid Leukaemia
The Ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia (AML) opened in February 1984 to all patients with primary or secondary forms of the disease; there was no age limit. Patients were randomised to receive either a 1 + 5 DAT combination (daunorubicin 50 mg/m2 i.v. on day 1, cytosine arabinoside 100 mg/m2 i.v. every 12 h on days 1–5, and 6-thioguanine 100 mg/m2 every 12 h on days 1–5) or a 3 +10 DAT regime (daunorubicin at the same dose on days 1, 3, and 5 and cytosine arabinoside and 6-thioguanine again at the same doses as in the 1 + 5 combination but on days 1–10).
KeywordsRemission Rate Acute Myeloid Leukaemia Cytosine Arabinoside Bone Marrow Blast Secondary Leukaemia
Unable to display preview. Download preview PDF.